<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00738673</url>
  </required_header>
  <id_info>
    <org_study_id>FE200486 CS27</org_study_id>
    <secondary_id>2008-000585-22</secondary_id>
    <nct_id>NCT00738673</nct_id>
  </id_info>
  <brief_title>Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer</brief_title>
  <official_title>An Open-Label, Multi-Centre, Uncontrolled, Exploratory Trial Investigating Degarelix One-Month Dosing Regimen as Second-Line Hormonal Treatment After PSA-Failure in GnRH Agonist Treated Patients With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was an open-label, multi-centre, uncontrolled, exploratory trial with a duration of 12
      months in two cohorts. The trial aimed to investigate Degarelix as a second-line hormonal
      treatment in Prostate Cancer patients who experienced PSA-Failure following
      gonadotropin-releasing hormone (GnRH) agonist treatment. The two cohorts differ in
      Testosterone levels at inclusion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants' Response in Prostate-Specific Antigen (PSA) Level at Three Months As Compared to Baseline</measure>
    <time_frame>Day 0 (baseline), 3 months</time_frame>
    <description>Response to treatment was defined as:
Response (stabilisation or decrease): Difference ≤ +10% of Baseline level
No response (increase): Difference &gt; +10% of Baseline level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants' Response in Prostate-Specific Antigen (PSA) Level at One Month As Compared to Baseline</measure>
    <time_frame>Day 0 (baseline), 1 month</time_frame>
    <description>Response to treatment was defined as:
Response (stabilisation or decrease): Difference ≤ +10% of Baseline level
No response (increase): Difference &gt; +10% of Baseline level.
Per protocol, the one month timeframe was only analyzed for cohort 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants' Response in Prostate-Specific Antigen (PSA) Level at Two Months As Compared to Baseline</measure>
    <time_frame>Day 0 (baseline), 2 months</time_frame>
    <description>Response to treatment was defined as:
Response (stabilisation or decrease): Difference ≤ +10% of Baseline level
No response (increase): Difference &gt; +10% of Baseline level.
Per protocol, the two month timeframe was only analyzed for cohort 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants at Testosterone Castrate Level Throughout the Study</measure>
    <time_frame>up to month 12</time_frame>
    <description>Participants who had no post-baseline serum testosterone level above castrate level which was &lt;=0.5 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Levels of Testosterone at the Last Visit</measure>
    <time_frame>Day 0 (baseline), up to month 12 (last visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Levels of Prostate-Specific Antigen (PSA) at Last Visit</measure>
    <time_frame>Day 0 (baseline), up to month 12 (last visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Levels of Luteinising Hormone (LH) at the Last Visit</measure>
    <time_frame>Day 0 (baseline), up to month 12 (last visit)</time_frame>
    <description>LH is measured in IU/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Levels of Follicle-Stimulating Hormone (FSH) at the Last Visit</measure>
    <time_frame>Day 0 (baseline), up to month 12 (last visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants at Testosterone Level &lt;=0.2 ng/mL Throughout the Study</measure>
    <time_frame>up to month 12</time_frame>
    <description>Participants in Cohort 2 who had no post-baseline serum testosterone level above 0.2 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants at Testosterone Level &lt;=0.32 ng/mL Throughout the Study</measure>
    <time_frame>up to month 12</time_frame>
    <description>Participants in Cohort 2 who had no post-baseline serum testosterone level above 0.32 ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Prostate-Specific Antigen (PSA) Progression Throughout the Study</measure>
    <time_frame>up to month 12</time_frame>
    <description>Counts of participants who had PSA progression during the study. PSA progression was defined as PSA &gt;+10% of baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate for Overall Survival</measure>
    <time_frame>up to month 12</time_frame>
    <description>The overall survival time was defined as number of days from first treatment dose to date of death. If a patient did not die then the patient's data were censored at the date of last visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Degarelix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0.
Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>degarelix</intervention_name>
    <description>Starting dose of 240 mg (40 mg/mL). Maintenance doses of 80 mg (20 mg/mL).</description>
    <arm_group_label>Degarelix</arm_group_label>
    <other_name>FE200486</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has given written informed consent before any trial-related activity is
             performed.

          -  Patient is 18 years or older.

          -  Histologically confirmed prostate cancer.

          -  Patient has received GnRH receptor agonist therapy for a duration of at least 12
             months (the first dose of GnRH-antagonist is to be administered when the next dose of
             the GnRH-agonist would have been due).

          -  Patient has experienced rising PSA levels although receiving GnRH agonist therapy,
             defined as two consecutive rises of PSA at least two weeks apart in two 50% increases
             over the nadir, and at least one PSA value of &gt;2.5 ng/mL within the last six months.

          -  Testosterone on castrate level (defined as ≤ 0.5 ng/mL) (cohort 1); Testosterone ≥0.2
             ng/mL at inclusion (cohort 2)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

          -  Estimated life expectancy at least 12 months.

        Exclusion Criteria:

          -  Previous history or presence of another malignancy, other than prostate cancer or
             treated squamous / basal cell carcinoma of the skin, within the last five years.

          -  Ongoing GnRH agonist therapy (last dose of previous GnRH agonist must have been
             received before Visit 1).

          -  Any pre-trial secondary hormonal manipulation (including antiandrogens) after PSA
             increase as described as above and before trial entry. Antiandrogens as part of
             complete androgen blockade must have been discontinued at least three months before
             first dose of trial medication.

          -  Previous or current treatment with chemotherapy (e.g. estramustine) for prostate
             cancer.

          -  Known hypersensitivity towards any component of the investigational medical product.

          -  History of severe uncontrolled asthma, anaphylactic reactions, or severe urticaria
             and/or angioedema.

          -  Known or suspected clinically significant liver and/or biliary disease.

          -  Any clinically significant laboratory abnormalities, disorders, or other condition,
             including alcohol or drug abuse, which may affect the patient's health or the outcome
             of the trial as judged by the Investigator.

          -  Patient has a clinically significant disorder (other than prostate cancer) including,
             but not limited to, renal, hematological, gastrointestinal, endocrine, cardiac,
             neurological, or psychiatric disease, and alcohol or drug abuse or any other
             condition, which may affect the patient's health or the outcome of the trial as judged
             by the Investigator.

          -  Patient has a mental incapacity or language barriers precluding adequate understanding
             or co-operation.

          -  Patient has received an investigational drug within the last 28 days preceding
             screening visit. Or longer if considered to possibly influencing the outcome of the
             current trial.

          -  Previous participation in any degarelix trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Bautzen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Klinik</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Borken</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Erkrath - Hochdal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Hagenow</city>
        <zip>19230</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martini Klinik</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Husum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Kirchheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Lauenburg/Elbe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Markkleeberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Klinik</name>
      <address>
        <city>Planegg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wissenschaftskontor Nord</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2008</study_first_submitted>
  <study_first_submitted_qc>August 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2008</study_first_posted>
  <results_first_submitted>December 12, 2012</results_first_submitted>
  <results_first_submitted_qc>December 12, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2013</results_first_posted>
  <last_update_submitted>December 12, 2012</last_update_submitted>
  <last_update_submitted_qc>December 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hormone refractory prostate cancer</keyword>
  <keyword>Agonist treatment failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deslorelin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Cohort 1 comprised a broad spectrum of biochemically relapsed participants (on castrate level) on long term hormonal treatment in different stages of the disease (primarily advance stages), however not in need of chemotherapy. The second cohort was similar, although testosterone levels were to be above castrate level (≥0.32 ng/mL).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Degarelix - Cohort 1</title>
          <description>Participants with baseline testosterone at castrate level. Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
        </group>
        <group group_id="P2">
          <title>Degarelix - Cohort 2</title>
          <description>Participants with baseline testosterone above castrate level (≥0.32 ng/mL ). Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent to Treat Population</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Degarelix - Cohort 1</title>
          <description>Participants with baseline testosterone at castrate level. Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
        </group>
        <group group_id="B2">
          <title>Degarelix - Cohort 2</title>
          <description>Participants with baseline testosterone above castrate level (≥0.32 ng/mL ). Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.7" spread="9.11"/>
                    <measurement group_id="B2" value="76.5" spread="4.68"/>
                    <measurement group_id="B3" value="73.9" spread="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIspanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.5" spread="17.3"/>
                    <measurement group_id="B2" value="87.6" spread="11.0"/>
                    <measurement group_id="B3" value="89.6" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.74" spread="0.06"/>
                    <measurement group_id="B2" value="1.72" spread="0.05"/>
                    <measurement group_id="B3" value="1.73" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage of Prostate Cancer at Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Localized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Locally advanced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not classifiable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage of Prostate Cancer at Enrolment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Localized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Locally advanced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not classifiable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gleason Score</title>
          <description>The 2005 International Society of Urological Pathologists recommendations for Gleason scoring were used to grade tumors. A primary grade is assigned to the most common tumor pattern (how the cancer cells look under a microscope), and a second grade to the next most common pattern. The two grades are added together to get a Gleason Score with a range of 2-10; 10=worst prognosis.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooporative Oncology Group (ECOG) Performance Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Fully active</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Restricted, but ambulatory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ambulatory, unable to work</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Capable of only limited selfcare</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completely disabled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants’ Response in Prostate-Specific Antigen (PSA) Level at Three Months As Compared to Baseline</title>
        <description>Response to treatment was defined as:
Response (stabilisation or decrease): Difference ≤ +10% of Baseline level
No response (increase): Difference &gt; +10% of Baseline level</description>
        <time_frame>Day 0 (baseline), 3 months</time_frame>
        <population>Intent to treat population. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix - Cohort 1</title>
            <description>Participants with baseline testosterone at castrate level. Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix - Cohort 2</title>
            <description>Participants with baseline testosterone above castrate level (≥0.32 ng/mL ). Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants’ Response in Prostate-Specific Antigen (PSA) Level at Three Months As Compared to Baseline</title>
          <description>Response to treatment was defined as:
Response (stabilisation or decrease): Difference ≤ +10% of Baseline level
No response (increase): Difference &gt; +10% of Baseline level</description>
          <population>Intent to treat population. Last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" lower_limit="4.74" upper_limit="37.38"/>
                    <measurement group_id="O2" value="33.33" lower_limit="9.92" upper_limit="65.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.33" lower_limit="62.62" upper_limit="95.26"/>
                    <measurement group_id="O2" value="66.67" lower_limit="34.89" upper_limit="90.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants’ Response in Prostate-Specific Antigen (PSA) Level at One Month As Compared to Baseline</title>
        <description>Response to treatment was defined as:
Response (stabilisation or decrease): Difference ≤ +10% of Baseline level
No response (increase): Difference &gt; +10% of Baseline level.
Per protocol, the one month timeframe was only analyzed for cohort 2.</description>
        <time_frame>Day 0 (baseline), 1 month</time_frame>
        <population>Full analysis set of participants with baseline and month 1 values. Per protocol, the one month timeframe was only analyzed for cohort 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix - Cohort 1</title>
            <description>Participants with baseline testosterone at castrate level. Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix - Cohort 2</title>
            <description>Participants with baseline testosterone above castrate level (≥0.32 ng/mL ). Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants’ Response in Prostate-Specific Antigen (PSA) Level at One Month As Compared to Baseline</title>
          <description>Response to treatment was defined as:
Response (stabilisation or decrease): Difference ≤ +10% of Baseline level
No response (increase): Difference &gt; +10% of Baseline level.
Per protocol, the one month timeframe was only analyzed for cohort 2.</description>
          <population>Full analysis set of participants with baseline and month 1 values. Per protocol, the one month timeframe was only analyzed for cohort 2.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="66.67" lower_limit="29.93" upper_limit="92.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="33.33" lower_limit="7.49" upper_limit="70.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants' Response in Prostate-Specific Antigen (PSA) Level at Two Months As Compared to Baseline</title>
        <description>Response to treatment was defined as:
Response (stabilisation or decrease): Difference ≤ +10% of Baseline level
No response (increase): Difference &gt; +10% of Baseline level.
Per protocol, the two month timeframe was only analyzed for cohort 2.</description>
        <time_frame>Day 0 (baseline), 2 months</time_frame>
        <population>Full analysis set of participants with baseline and month 2 values. Per protocol, the two month timeframe was only analyzed for cohort 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix - Cohort 1</title>
            <description>Participants with baseline testosterone at castrate level. Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix - Cohort 2</title>
            <description>Participants with baseline testosterone above castrate level (≥0.32 ng/mL ). Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants' Response in Prostate-Specific Antigen (PSA) Level at Two Months As Compared to Baseline</title>
          <description>Response to treatment was defined as:
Response (stabilisation or decrease): Difference ≤ +10% of Baseline level
No response (increase): Difference &gt; +10% of Baseline level.
Per protocol, the two month timeframe was only analyzed for cohort 2.</description>
          <population>Full analysis set of participants with baseline and month 2 values. Per protocol, the two month timeframe was only analyzed for cohort 2.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="40.00" lower_limit="12.16" upper_limit="73.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="60.00" lower_limit="26.24" upper_limit="87.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants at Testosterone Castrate Level Throughout the Study</title>
        <description>Participants who had no post-baseline serum testosterone level above castrate level which was &lt;=0.5 ng/mL.</description>
        <time_frame>up to month 12</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix - Cohort 1</title>
            <description>Participants with baseline testosterone at castrate level. Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix - Cohort 2</title>
            <description>Participants with baseline testosterone above castrate level (≥0.32 ng/mL ). Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants at Testosterone Castrate Level Throughout the Study</title>
          <description>Participants who had no post-baseline serum testosterone level above castrate level which was &lt;=0.5 ng/mL.</description>
          <population>Intent to treat population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Levels of Testosterone at the Last Visit</title>
        <time_frame>Day 0 (baseline), up to month 12 (last visit)</time_frame>
        <population>Intent to treat population with a baseline and at least one scheduled post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix - Cohort 1</title>
            <description>Participants with baseline testosterone at castrate level. Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix - Cohort 2</title>
            <description>Participants with baseline testosterone above castrate level (≥0.32 ng/mL ). Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Levels of Testosterone at the Last Visit</title>
          <population>Intent to treat population with a baseline and at least one scheduled post-baseline measurement.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.039" spread="0.175"/>
                    <measurement group_id="O2" value="-0.038" spread="0.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Levels of Prostate-Specific Antigen (PSA) at Last Visit</title>
        <time_frame>Day 0 (baseline), up to month 12 (last visit)</time_frame>
        <population>Intent to treat population with a baseline and at least one scheduled post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix - Cohort 1</title>
            <description>Participants with baseline testosterone at castrate level. Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix - Cohort 2</title>
            <description>Participants with baseline testosterone above castrate level (≥0.32 ng/mL ). Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Levels of Prostate-Specific Antigen (PSA) at Last Visit</title>
          <population>Intent to treat population with a baseline and at least one scheduled post-baseline measurement.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="29"/>
                    <measurement group_id="O2" value="54" spread="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Levels of Luteinising Hormone (LH) at the Last Visit</title>
        <description>LH is measured in IU/L</description>
        <time_frame>Day 0 (baseline), up to month 12 (last visit)</time_frame>
        <population>Intent to treat population with a baseline and at least one scheduled post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix - Cohort 1</title>
            <description>Participants with baseline testosterone at castrate level. Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix - Cohort 2</title>
            <description>Participants with baseline testosterone above castrate level (≥0.32 ng/mL ). Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Levels of Luteinising Hormone (LH) at the Last Visit</title>
          <description>LH is measured in IU/L</description>
          <population>Intent to treat population with a baseline and at least one scheduled post-baseline measurement.</population>
          <units>percentage of baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" spread="286"/>
                    <measurement group_id="O2" value="123" spread="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Levels of Follicle-Stimulating Hormone (FSH) at the Last Visit</title>
        <time_frame>Day 0 (baseline), up to month 12 (last visit)</time_frame>
        <population>Intent to treat population with a baseline and at least one scheduled post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix - Cohort 1</title>
            <description>Participants with baseline testosterone at castrate level. Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix - Cohort 2</title>
            <description>Participants with baseline testosterone above castrate level (≥0.32 ng/mL ). Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Levels of Follicle-Stimulating Hormone (FSH) at the Last Visit</title>
          <population>Intent to treat population with a baseline and at least one scheduled post-baseline measurement.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.64" spread="3.01"/>
                    <measurement group_id="O2" value="-2.01" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants at Testosterone Level &lt;=0.2 ng/mL Throughout the Study</title>
        <description>Participants in Cohort 2 who had no post-baseline serum testosterone level above 0.2 ng/mL.</description>
        <time_frame>up to month 12</time_frame>
        <population>Full analysis set. Per the protocol, this analysis was only performed on Cohort 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix - Cohort 1</title>
            <description>Participants with baseline testosterone at castrate level. Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix - Cohort 2</title>
            <description>Participants with baseline testosterone above castrate level (≥0.32 ng/mL ). Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants at Testosterone Level &lt;=0.2 ng/mL Throughout the Study</title>
          <description>Participants in Cohort 2 who had no post-baseline serum testosterone level above 0.2 ng/mL.</description>
          <population>Full analysis set. Per the protocol, this analysis was only performed on Cohort 2.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants at Testosterone Level &lt;=0.32 ng/mL Throughout the Study</title>
        <description>Participants in Cohort 2 who had no post-baseline serum testosterone level above 0.32 ng/mL</description>
        <time_frame>up to month 12</time_frame>
        <population>Full analysis set. Per the protocol, this analysis was only performed on Cohort 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix - Cohort 1</title>
            <description>Participants with baseline testosterone at castrate level. Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix - Cohort 2</title>
            <description>Participants with baseline testosterone above castrate level (≥0.32 ng/mL ). Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants at Testosterone Level &lt;=0.32 ng/mL Throughout the Study</title>
          <description>Participants in Cohort 2 who had no post-baseline serum testosterone level above 0.32 ng/mL</description>
          <population>Full analysis set. Per the protocol, this analysis was only performed on Cohort 2.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Prostate-Specific Antigen (PSA) Progression Throughout the Study</title>
        <description>Counts of participants who had PSA progression during the study. PSA progression was defined as PSA &gt;+10% of baseline value.</description>
        <time_frame>up to month 12</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix - Cohort 1</title>
            <description>Participants with baseline testosterone at castrate level. Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix - Cohort 2</title>
            <description>Participants with baseline testosterone above castrate level (≥0.32 ng/mL ). Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Prostate-Specific Antigen (PSA) Progression Throughout the Study</title>
          <description>Counts of participants who had PSA progression during the study. PSA progression was defined as PSA &gt;+10% of baseline value.</description>
          <population>Intent to treat population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate for Overall Survival</title>
        <description>The overall survival time was defined as number of days from first treatment dose to date of death. If a patient did not die then the patient’s data were censored at the date of last visit.</description>
        <time_frame>up to month 12</time_frame>
        <population>Intent to treat population.
Analysis was not performed since no participants died during study.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix - Cohort 1</title>
            <description>Participants with baseline testosterone at castrate level. Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix - Cohort 2</title>
            <description>Participants with baseline testosterone above castrate level (≥0.32 ng/mL ). Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate for Overall Survival</title>
          <description>The overall survival time was defined as number of days from first treatment dose to date of death. If a patient did not die then the patient’s data were censored at the date of last visit.</description>
          <population>Intent to treat population.
Analysis was not performed since no participants died during study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to month 13</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Degarelix - Cohort 1</title>
          <description>Participants with baseline testosterone at castrate level. Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
        </group>
        <group group_id="E2">
          <title>Degarelix - Cohort 2</title>
          <description>Participants with baseline testosterone above castrate level (≥0.32 ng/mL ). Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0. Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia of malignant disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Venous stasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

